Top fund manager names these 2 ASX shares as buys

WAM Research has named two ASX shares that it thinks could be opportunities.
The post Top fund manager names these 2 ASX shares as buys appeared first on The Motley Fool Australia. –

High-performing fund manager Wilson Asset Management (WAM) has revealed two ASX shares that it rates as buys within the WAM Research Limited (ASX: WAX) portfolio.

WAM operates several listed investment companies (LICs). Two of those LICs are WAM Capital Limited (ASX: WAM) and WAM Leaders Ltd (ASX: WLE).

One of the LICs is called WAM Research, which looks at smaller businesses on the ASX.

WAM describes WAM Research as a LIC that invests in the most compelling undervalued growth opportunities in the Australian market.

The WAM Research portfolio has delivered gross returns (that’s before fees, expenses and taxes) of 16.3% per annum since the strategy changed in July 2010, which is superior to the S&P/ASX All Ordinaries Accumulation Index return of 9.5% per annum.

These are the two ASX shares that WAM outlined in its most recent monthly update:

Virtus Health Ltd (ASX: VRT)

Virtus Health is a fertility business. WAM Research explains that it helps more than 5,000 people become parents each year as the largest provider of assisted reproductive services in Australia, the market leader in Ireland and Denmark, and a growing presence in Singapore and the UK.

It operates 43 in vitro fertilisation (IVF) clinics globally, as well as seven day hospitals and the Virtus diagnostic and pathology service.

As it recovers from the impacts of the COVID-19 pandemic, Virtus is seeing a “strong uplift” in demand for IVF services.

The ASX share is considering licensing its technology through its precision fertility capabilities to other IVF players globally. WAM Research said this would be a revenue stream which is not capital intensive, and a strategy the fund manager believes will see significant upside.

The fund manager is also positive on Virtus Health CEO Kate Munnings, who was appointed in March 2020. WAM Research thinks Ms Munnings has the ability to monetise the intellectual property within the organisation to pursue other revenue sources in precision fertility, genetics testing and digitalisation.

Fletcher Building Limited (ASX: FBU)

The other ASX share that WAM Research referred to was Fletcher Building, which is a manufacturer, home builder and partner on major construction and infrastructure projects.

The fund manager pointed out that in May, Fletcher Building announced that earnings before interest, tax, depreciation and amortisation (EBITDA) for FY21 is expected to be between $650 million to $665 million, which is at the upper end of its previous guidance range.

WAM Research also referred to the capital return that Fletcher Building is going to return to investors in the form of a NZ$300 million on-market share buyback as a result of its strong balance sheet.

The fund manager is positive on the ASX share as building market activity remains robust and government stimulus continues to support the sector. This will underpin the delivery of a “strong” uplift in EBITDA margins over the next one or two years.

The post Top fund manager names these 2 ASX shares as buys appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Top brokers name 3 ASX shares to sell today

Why the Fletcher Building (ASX:FBU) share price just hit a 52-week high
ASX 200 drops, ALS jumps, Fletcher Building rises

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Virtus Health Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!